PIM3 antibody (C-Term)

Catalog No. ABIN2841313

There are 5+ publications for this product available. The Rabbit Polyclonal anti-PIM3 antibody is suitable to detect PIM3 in samples from Human and Mouse. It has been validated for WB and IHC (p).

Quick Overview for PIM3 antibody (C-Term) (ABIN2841313)

Target: PIM3 (Pim-3 Oncogene (PIM3))

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PIM3 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RB8591

Product Details anti-PIM3 Antibody

Binding Specificity: AA 259-288, C-Term

Predicted Reactivity: Rat

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This PIM3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 259-288 amino acids from the C-terminal region of human PIM3.

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000. IHC-P: 1:10~50. IHC-P: 1:10~50

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Expiry Date: 6 months

References for anti-PIM3 antibody (ABIN2841313)

Ishikawa, Senba, Hashimoto, Imaizumi, Mori: "Expression and significance of Pim-3 kinase in adult T-cell leukemia." in: European journal of haematology, Vol. 99, Issue 6, pp. 495-504, (2018) (PubMed).

Decker, Finter, Forde, Kissel, Schwaller, Mack, Kuhn, Gray, Follo, Jumaa, Burger, Zirlik, Pfeifer, Miduturu, Eibel, Veelken, Dierks: "PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1)." in: Molecular cancer therapeutics, Vol. 13, Issue 5, pp. 1231-45, (2014) (PubMed).

Brault, Menter, Obermann, Knapp, Thommen, Schwaller, Tzankov: "PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma." in: British journal of cancer, Vol. 107, Issue 3, pp. 491-500, (2012) (PubMed).

Chen, Redkar, Bearss, Wierda, Gandhi: "Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells." in: Blood, Vol. 114, Issue 19, pp. 4150-7, (2009) (PubMed).

Cheng, Weidner-Glunde, Varjosalo, Rainio, Lehtonen, Schulz, Koskinen, Taipale, Ojala: "KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA." in: PLoS pathogens, Vol. 5, Issue 3, pp. e1000324, (2009) (PubMed).

Target Details for PIM3

Target: PIM3 (Pim-3 Oncogene (PIM3))

Alternative Name: PIM3

Background: PIM3 is a memberof the Ser/Thr protein kinase family that may be involved in cell cycle progression and anti-apoptosis process. This protein has been implicated in proliferation of human hepatoma cell lines. PIM3 is widely expressed, with the exception of no expression observed in colon, thymus, and small intestine. PIM3 is expressed in human hepatoma cell lines but not in normal liver tissues.

Molecular Weight: 35891

Gene ID: 415116

NCBI Accession: NP_001001852

UniProt: Q86V86

Pathways: Negative Regulation of Hormone Secretion